日本語
 
Help Privacy Policy ポリシー/免責事項
  詳細検索ブラウズ

アイテム詳細

登録内容を編集ファイル形式で保存
 
 
ダウンロード電子メール
  The future of technologies for personalised medicine

Harvey, A., Brand, A., Holgate, S. T., Kristiansen, L. V., Lehrach, H., Palotie, A., & Prainsack, B. (2012). The future of technologies for personalised medicine. New Biotechnology, 29(6), 625-633. doi:10.1016/j.nbt.2012.03.009.

Item is

基本情報

表示: 非表示:
資料種別: 学術論文

ファイル

表示: ファイル
非表示: ファイル
:
Harvey.pdf (出版社版), 506KB
ファイルのパーマリンク:
https://hdl.handle.net/11858/00-001M-0000-000E-F770-C
ファイル名:
Harvey.pdf
説明:
-
OA-Status:
閲覧制限:
公開
MIMEタイプ / チェックサム:
application/pdf / [MD5]
技術的なメタデータ:
著作権日付:
2012
著作権情報:
2012 Elsevier B.V. All rights reserved.
CCライセンス:
-

関連URL

表示:

作成者

表示:
非表示:
 作成者:
Harvey, Alison1, 著者
Brand, Angela2, 3, 著者
Holgate, Stephen T.2, 4, 著者
Kristiansen, Lars V.5, 著者
Lehrach, Hans6, 著者           
Palotie, Aarno2, 7, 8, 著者
Prainsack, Barbara2, 9, 著者
所属:
1Finchley Court, Norwich, UK, ou_persistent22              
2 Scientific Committee for the ESF Forward Look on Personalised Medicine for the European Citizen, France, ou_persistent22              
3Institute for Public Health Genomics, Maastricht University, The Netherlands, ou_persistent22              
4Faculty of Medicine, University of Southampton, Southampton, UK, ou_persistent22              
5Biomedical Sciences Unit, the European Science Foundation, Strasbourg, France, ou_persistent22              
6Dept. of Vertebrate Genomics (Head: Hans Lehrach), Max Planck Institute for Molecular Genetics, Max Planck Society, Ihnestr. 63-74, Berlin, ou_1433550              
7Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, ou_persistent22              
8The Wellcome Trust Sanger Institute, Cambridge, UK, ou_persistent22              
9Brunel University, Uxbridge Middlesex, UK, ou_persistent22              

内容説明

表示:
非表示:
キーワード: Health Information Systems Health Resources Humans Individualized Medicine/*methods/*trends Translational Medical Research
 要旨: Personalised medicine promises prediction, prevention and treatment of illness that is targeted to individuals' needs. New technologies for detailed biological profiling of individuals at the molecular level have been crucial in initiating the move to personalised medicine; further novel technologies will be necessary if the vision is to become a reality. We will need to develop new technologies to collect and analyse data in a way that is not just linear but integrated (understanding system level functioning) and dynamic (understanding system in flux). Key factors in the development of technologies for personalised medicine are standardisation, integration and harmonisation. For example, the tools and processes for data collection and analysis must be standardised across research sites. Research activity at different sites must be integrated to maximise synergies, and scientific research must be integrated with healthcare to ensure effective translation. There must also be harmonisation between scientific practices in different research sites, between science and healthcare and between science, healthcare and wider society, including the ethical and regulatory frameworks, the prevailing political and cultural ethos and the expectations of patients/citizens.

資料詳細

表示:
非表示:
言語: eng - English
 日付: 2012-09-152012
 出版の状態: 出版
 ページ: 8
 出版情報: -
 目次: -
 査読: -
 識別子(DOI, ISBNなど): DOI: 10.1016/j.nbt.2012.03.009
 学位: -

関連イベント

表示:

訴訟

表示:

Project information

表示:

出版物 1

表示:
非表示:
出版物名: New Biotechnology
種別: 学術雑誌
 著者・編者:
所属:
出版社, 出版地: Elsevier
ページ: 13 巻号: 29 (6) 通巻号: - 開始・終了ページ: 625 - 633 識別子(ISBN, ISSN, DOIなど): -